Pharmacoeconomic review report : indication : an add-on maintenance treatment of adult patients with severe eosinophilic asthma. Benralizumab (Fasenra) (AstraZeneca Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Pharmacoepidemiology.

Physical Description:

1 online resource (34 pages) : illustrations

Edition:

Final with redactions.

Place of Publication:

Canada : CADTH, 2018.

Summary:

Benralizumab (Fasenra) is a targeted, humanized monoclonal antibody indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma. The recommended dose is 30 mg administered via subcutaneous injection once every four weeks for the first three doses, and then once every eight weeks thereafter. It is supplied as a solution for injection in a 30 mg/mL syringe. The submitted price of benralizumab is 3,876.92 per syringe injection, resulting in an annual cost of 31,015 in year 1 and 25,200 in subsequent years. The requested reimbursement criteria are: for add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with a high-dose inhaled corticosteroid (ICS) and one or more additional asthma controller(s) (e.g., longacting beta2 agonist [LABA]), if: blood eosinophil count of ≥ 300 cells/μL AND have experienced two or more clinically significant asthma exacerbations in the past 12 months; or blood eosinophil count of ≥ 150 cells/μL AND are treated chronically with oral corticosteroids (OCS). The manufacturer submitted cost-utility analyses that assessed benralizumab + standard of care (SOC: high-dose ICS + LABA (+/-) OCS) in adult patients with severe uncontrolled eosinophilic asthma over a lifetime (approximately 50-year) time horizon from the perspective of the Canadian health care payer.

Notes:

Description based on publisher supplied metadata and other sources.